Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • Board of directors
    • Our management team
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics
      • When to perform TDM ?
      • Results interpretation
      • Therapeutic Thresholds
      • Tracker Publications
      • Guidelines
      • Frequently asked questions
    • TRACKER
      • LISA TRACKER
      • i-Tracker
      • i-Track 10
      • ez-Track1 & ez-Tracker
      • Immunotrol Tracker
    • Patient Stratification – PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Our management team
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Autres informations réglementées

  1. Home>
  2. Investors>
  3. Regulated information>
  4. Autres informations réglementées

2022

7 décembre 2022 : Note établie par Theradiag en réponse à l’OPA visant ses actions initiée par Biosynex

7 décembre 2022 : Informations relatives aux caractéristiques, notamment juridiques, financières et comptables, de la société Theradiag

Projet de note en réponse établi par la société Theradiag en réponse à l’offre publique d’achat visant les actions de la société Theradiag initiée par la société Biosynex

2021

Avis BALO Augmentation de capital publié le 29 octobre 2021

Bilan du Contrat de liquidité du 1er semestre 2021 publié le 6 juillet 2021

Bilan du Contrat de liquidité du 2nd semestre 2020 publié le 07 janvier 2021

2020

Bilan du Contrat de liquidité au 30 juin 2020 publié le 6 juillet 2020

Bilan du Contrat de liquidité du 2nd semestre 2019 publié le 08 janvier 2020

2019

Bilan du contrat de liquidité au 30 juin 2019 publié le 4 juillet 2019

Latest Press Releases

  • 18/09/2023: Theradiag announces its 2023 half-year results and reports a significant improvement in profitability
    18 September 2023/
    0 Comments
  • 17/07/2023: Theradiag reports revenue for the first half 2023
    17 July 2023/
    0 Comments
  • 12/04/2023: Theradiag announces its 2022 full-year results and 2023 first quarter revenue
    12 April 2023/
    0 Comments

Events

25 - 28 Sep 2023

EURACHEM PT 2023

De Vere Beaumont Estate hotel
27 - 29 Sep 2023

28th FFER days

Palais des Congrès d'Arcachon
29 - 30 Sep 2023

12th MICI ouest days

Couvent des Jacobins
No event found!
Load More

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • Board of directors
    • Our management team
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics
      • When to perform TDM ?
      • Results interpretation
      • Therapeutic Thresholds
      • Tracker Publications
      • Guidelines
      • Frequently asked questions
    • TRACKER
      • LISA TRACKER
      • i-Tracker
      • i-Track 10
      • ez-Track1 & ez-Tracker
      • Immunotrol Tracker
    • Patient Stratification – PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Our management team
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English